Edrophonium

Publication Details

Estimated reading time: 1 minute

CASRN: 312-48-1

image 134974646 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Edrophonium is no longer marketed in the US. No information is available on the use of edrophonium during breastfeeding. However, because of its short half-life and quaternary ammonium structure, it is unlikely to be excreted into breastmilk or orally absorbed by the infant. Administering the drug just after breastfeeding and waiting 2 to 3 hours before breastfeeding again should avoid any adverse reactions in the infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Edrophonium

CAS Registry Number

312-48-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Cholinesterase Inhibitors

Diagnostic Agents

Parasympathomimetics

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.